Cinctive Capital Management LP Sells 1,172 Shares of Regeneron Pharmaceuticals, Inc. $REGN

Cinctive Capital Management LP reduced its stake in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 37.7% during the third quarter, according to its most recent filing with the SEC. The fund owned 1,937 shares of the biopharmaceutical company’s stock after selling 1,172 shares during the quarter. Cinctive Capital Management LP’s holdings in Regeneron Pharmaceuticals were worth $1,089,000 at the end of the most recent quarter.

Several other institutional investors also recently added to or reduced their stakes in REGN. Brighton Jones LLC boosted its stake in Regeneron Pharmaceuticals by 261.8% in the fourth quarter. Brighton Jones LLC now owns 948 shares of the biopharmaceutical company’s stock valued at $675,000 after acquiring an additional 686 shares during the last quarter. Dynamic Technology Lab Private Ltd bought a new stake in shares of Regeneron Pharmaceuticals in the 1st quarter worth approximately $226,000. Commonwealth of Pennsylvania Public School Empls Retrmt SYS raised its holdings in shares of Regeneron Pharmaceuticals by 5.9% in the 2nd quarter. Commonwealth of Pennsylvania Public School Empls Retrmt SYS now owns 25,469 shares of the biopharmaceutical company’s stock worth $13,371,000 after purchasing an additional 1,409 shares during the period. Citizens Financial Group Inc. RI lifted its stake in Regeneron Pharmaceuticals by 237.4% in the second quarter. Citizens Financial Group Inc. RI now owns 2,659 shares of the biopharmaceutical company’s stock valued at $1,396,000 after purchasing an additional 1,871 shares during the last quarter. Finally, Dorsey & Whitney Trust CO LLC lifted its stake in Regeneron Pharmaceuticals by 40.2% in the second quarter. Dorsey & Whitney Trust CO LLC now owns 506 shares of the biopharmaceutical company’s stock valued at $266,000 after purchasing an additional 145 shares during the last quarter. Institutional investors own 83.31% of the company’s stock.

Regeneron Pharmaceuticals Trading Up 1.5%

NASDAQ:REGN opened at $756.91 on Tuesday. Regeneron Pharmaceuticals, Inc. has a 1 year low of $476.49 and a 1 year high of $821.11. The stock’s fifty day moving average price is $769.61 and its two-hundred day moving average price is $696.93. The company has a debt-to-equity ratio of 0.09, a current ratio of 4.13 and a quick ratio of 3.39. The company has a market cap of $80.02 billion, a P/E ratio of 18.21, a P/E/G ratio of 2.00 and a beta of 0.40.

Regeneron Pharmaceuticals (NASDAQ:REGN) last announced its quarterly earnings results on Friday, January 30th. The biopharmaceutical company reported $11.44 earnings per share for the quarter, beating the consensus estimate of $10.74 by $0.70. Regeneron Pharmaceuticals had a return on equity of 13.04% and a net margin of 31.41%.The company had revenue of $3.88 billion during the quarter, compared to analysts’ expectations of $3.76 billion. During the same period in the previous year, the business earned $12.07 earnings per share. The firm’s quarterly revenue was up 2.5% compared to the same quarter last year. As a group, analysts expect that Regeneron Pharmaceuticals, Inc. will post 35.92 EPS for the current year.

Regeneron Pharmaceuticals Increases Dividend

The business also recently announced a quarterly dividend, which was paid on Thursday, March 5th. Shareholders of record on Friday, February 20th were issued a dividend of $0.94 per share. This represents a $3.76 dividend on an annualized basis and a yield of 0.5%. The ex-dividend date of this dividend was Friday, February 20th. This is a boost from Regeneron Pharmaceuticals’s previous quarterly dividend of $0.88. Regeneron Pharmaceuticals’s payout ratio is presently 9.05%.

Insider Buying and Selling

In other news, Director Bonnie L. Bassler sold 1,500 shares of the company’s stock in a transaction dated Wednesday, January 7th. The stock was sold at an average price of $800.00, for a total transaction of $1,200,000.00. Following the sale, the director directly owned 1,703 shares in the company, valued at $1,362,400. This represents a 46.83% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available at this link. Also, SVP Jason Pitofsky sold 2,036 shares of the stock in a transaction dated Monday, February 9th. The stock was sold at an average price of $778.52, for a total transaction of $1,585,066.72. Following the completion of the sale, the senior vice president directly owned 4,272 shares in the company, valued at approximately $3,325,837.44. The trade was a 32.28% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. In the last ninety days, insiders have sold 5,274 shares of company stock valued at $4,142,738. Corporate insiders own 7.02% of the company’s stock.

Wall Street Analyst Weigh In

A number of analysts have issued reports on REGN shares. BMO Capital Markets raised their target price on Regeneron Pharmaceuticals from $725.00 to $850.00 and gave the stock an “outperform” rating in a research report on Thursday, December 4th. Wells Fargo & Company upped their price target on Regeneron Pharmaceuticals from $745.00 to $800.00 and gave the company an “equal weight” rating in a research report on Monday, February 2nd. Royal Bank Of Canada increased their price target on Regeneron Pharmaceuticals from $745.00 to $765.00 and gave the stock a “sector perform” rating in a research note on Monday, March 2nd. HSBC raised Regeneron Pharmaceuticals to a “strong-buy” rating in a report on Monday, November 24th. Finally, JPMorgan Chase & Co. upped their price objective on shares of Regeneron Pharmaceuticals from $850.00 to $950.00 and gave the company an “overweight” rating in a report on Monday, February 2nd. Two equities research analysts have rated the stock with a Strong Buy rating, fifteen have given a Buy rating and nine have issued a Hold rating to the company. According to MarketBeat.com, Regeneron Pharmaceuticals currently has a consensus rating of “Moderate Buy” and an average price target of $802.27.

About Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc (NASDAQ: REGN) is a U.S.-based biotechnology company founded in 1988 and headquartered in Tarrytown, New York. It focuses on discovering, developing, manufacturing and commercializing medicines for serious medical conditions. The company combines laboratory research, clinical development and in-house manufacturing to advance a pipeline of biologic therapies across multiple therapeutic areas.

Regeneron is known for its proprietary drug discovery technologies, including its VelocImmune platform, which is used to generate fully human monoclonal antibodies.